trabodenoson
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2010 (NCT01123772)
Timeline
Indications
Mechanism of action
- Adenosine A1 receptorAGONIST
ADORA1 agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=[N+]([O-])OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O- Mol. weight
- 380.36 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545407 ↗
Also known as
- inno-8875
- inno-8875
- ino-8875
- ino-8875
- ino-8875
- pj-875
- pj-875
- trabodenoson
- trabodenoson
- trabodenoson
- trabodenoson
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02829996 | Phase 2 | Aug 19, 2016 | Inotek |
| NCT02565173 | Phase 3 | Sep 1, 2015 | Inotek |
| NCT01917383 | Phase 2 | Aug 1, 2013 | Inotek |
| NCT01123772 | Phase 1 | May 1, 2010 | Inotek |
| NCT01123785 | Phase 1/Phase 2 (Phase 2) | May 1, 2010 | Inotek |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inotek | For profit | 5 | 5 | 3 | 2010 |
1 organizations
Page 1 / 1